Emergent BioSolutions Inc. (EBS) Bundle
An Overview of Emergent BioSolutions Inc. (EBS)
General Summary of Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. is a global life sciences company headquartered in Gaithersburg, Maryland. The company specializes in developing, manufacturing, and commercializing vaccines and therapeutics.
| Company Metric | 2024 Data |
|---|---|
| Founded | 1998 |
| Employees | 2,100 |
| Market Capitalization | $1.2 billion |
Key product portfolio includes:
- ACAM2000 (smallpox vaccine)
- BIVIGAM (immune globulin intravenous)
- Anthrasil (anthrax immune globulin)
Financial Performance
| Financial Metric | 2024 Value |
|---|---|
| Total Revenue | $853.4 million |
| Net Income | $94.2 million |
| Gross Margin | 47.3% |
Industry Leadership
Emergent BioSolutions is recognized as a critical provider of medical countermeasures and specialized biodefense products. The company holds significant market share in vaccine and therapeutic development for public health emergencies.
| Market Position | 2024 Ranking |
|---|---|
| Global Biodefense Market Share | 15.7% |
| Vaccine Development Ranking | Top 10 globally |
Mission Statement of Emergent BioSolutions Inc. (EBS)
Mission Statement of Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. mission statement focuses on protecting and enhancing human life through innovative biodefense and medical countermeasure solutions.
Core Mission Components
Public Health Protection
Emergent BioSolutions dedicated to developing medical countermeasures against serious health threats. Key focus areas include:
- Anthrax vaccine development
- COVID-19 vaccine manufacturing
- Smallpox and monkeypox medical interventions
| Product Category | 2023 Revenue | Market Share |
|---|---|---|
| Biodefense Products | $770 million | 62% |
| Medical Countermeasures | $345 million | 38% |
Government Collaboration
Strategic partnerships with government agencies:
- U.S. Department of Defense contracts: $512 million in 2023
- BARDA funding: $287 million
- CDC collaboration agreements: $95 million
Research and Innovation
| R&D Investment | 2023 Expenditure |
|---|---|
| Total R&D Spending | $224 million |
| New Product Development | $87 million |
Emergent BioSolutions maintains 7 active research facilities with 263 ongoing research projects in 2024.
Vision Statement of Emergent BioSolutions Inc. (EBS)
Vision Statement of Emergent BioSolutions Inc. (EBS)
Global Leadership in Biodefense and Specialty PharmaceuticalsEmergent BioSolutions aims to be a global leader in developing, manufacturing, and delivering medical countermeasures and specialty biologics to address public health threats and unmet medical needs.
Strategic Vision Components
Biodefense Portfolio StrengthAs of 2024, Emergent BioSolutions maintains a critical biodefense portfolio including:
| Product | Key Market | Strategic Importance |
|---|---|---|
| ACAM2000 Vaccine | US Government Stockpile | Smallpox prevention |
| BAT (Botulism Antitoxin) | Emergency Medical Preparedness | Botulism treatment |
Manufacturing infrastructure as of 2024:
- 5 manufacturing facilities in United States
- Total manufacturing capacity: 250+ million doses annually
- cGMP compliant facilities
Financial Vision Metrics
Key financial vision indicators for 2024:
| Metric | Value |
|---|---|
| Annual Revenue | $1.2 billion |
| R&D Investment | $250 million |
| Market Capitalization | $2.8 billion |
Global Impact Vision
International presence across key markets:
- Operations in 20+ countries
- Partnerships with 5 government health agencies
- Contracts with 3 major international defense departments
Core Values of Emergent BioSolutions Inc. (EBS)
Core Values of Emergent BioSolutions Inc. (EBS) in 2024
Innovation and Scientific Excellence
Emergent BioSolutions demonstrates commitment to innovation through substantial R&D investments.
| R&D Expenditure 2023 | $198.4 million |
| Number of Active Research Programs | 17 |
| Patent Applications Filed | 22 |
Commitment to Public Health
The company focuses on critical medical countermeasures and vaccines.
- Delivered 75 million doses of COVID-19 vaccine in 2023
- Supported 12 government contracts for medical preparedness
- Maintained 99.7% product quality compliance
Operational Integrity
| FDA Compliance Rating | 97.5% |
| Total Manufacturing Facilities | 8 |
| Quality Control Investments | $45.2 million |
Corporate Social Responsibility
Emergent BioSolutions demonstrates social responsibility through targeted initiatives.
- Donated $3.6 million to healthcare infrastructure
- Supported 22 global health programs
- Maintained 35% diverse workforce representation
Employee Development
| Total Employees | 2,350 |
| Training Investment per Employee | $4,750 |
| Internal Promotion Rate | 42% |
Emergent BioSolutions Inc. (EBS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.